Form 4: Amylyx Pharmaceuticals CFO James M. Frates Sells Shares to Cover Tax Obligations

James M. Frates, CFO of Amylyx Pharmaceuticals, sold 10,896 shares of common stock on March 31, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 31, 2025, James M. Frates, the Chief Financial Officer of Amylyx Pharmaceuticals, sold 10,896 shares of the company's common stock.
• The sale was executed at a weighted average price ranging from $3.44 to $3.58 per share.
• The total shares beneficially owned following the transaction are 290,988 shares directly and 15,459 and 11,072 indirectly through trusts.
• The sale was to cover tax withholding obligations associated with the vesting of restricted stock units and was automatic, not discretionary.
• Frates also holds shares indirectly through the James M. Frates 2024 Grantor Retained Annuity Trust No. 1 and the FRATES FAMILY 2013 IRREV TRUST, for which he serves as trustee.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to an insider stock sale for tax purposes. It doesn't indicate any significant positive or negative developments for the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Comparison to Industry Standards

• Insider sales to cover tax obligations on vesting equity are a common practice across publicly traded companies.
• The size of the sale (10,896 shares) is relatively small compared to the total direct holdings (290,988 shares), suggesting it's a routine transaction rather than a significant divestment.
• Comparable companies in the pharmaceutical sector also see similar Form 4 filings from their executives.

Stakeholder Impact

• The stock sale may have a minor, temporary impact on the stock price due to the increased selling pressure.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Amylyx Pharmaceuticals, AMLX, James M. Frates, CFO, Stock Sale, Beneficial Ownership, Restricted Stock Units, Tax Withholding